Publications

European journal of cancer (Oxford, England : 1990)

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

01-03-2017

Annals of oncology : official journal of the European Society for Medical Oncology

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

01-03-2017

Oncoimmunology

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

27-01-2017

Acta oncologica (Stockholm, Sweden)

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.

01-01-2017

Journal of clinical pharmacology

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

01-01-2017

Ecancermedicalscience

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

21-12-2016

International journal of molecular sciences

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten^LoxP/LoxP;Braf^CA/+ Mice.

20-12-2016

The Lancet. Oncology

Biomarkers for outcome upon MAPK inhibition in melanoma.

01-12-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

15-11-2016

Cell metabolism

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

08-11-2016

European journal of cancer (Oxford, England : 1990)

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

01-11-2016

Journal of clinical pharmacology

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

01-10-2016

Cancer immunology, immunotherapy : CII

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

01-09-2016

European journal of cancer (Oxford, England : 1990)

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

01-09-2016

World journal of urology

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.

01-08-2016

World journal of urology

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

01-08-2016

Nederlands tijdschrift voor geneeskunde

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

22-07-2016

Cell reports

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

28-06-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

15-06-2016

Annals of oncology : official journal of the European Society for Medical Oncology

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

01-06-2016

Cancer immunology, immunotherapy : CII

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

01-06-2016

Science (New York, N.Y.)

CANCER IMMUNOLOGY. The "cancer immunogram".

06-05-2016

Clinical cancer research : an official journal of the American Association for Cancer Research

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

01-05-2016

Science (New York, N.Y.)

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

09-10-2015

Cancer immunology, immunotherapy : CII

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

01-10-2015

Molecular therapy : the journal of the American Society of Gene Therapy

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

01-09-2015

EMBO molecular medicine

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

01-09-2015

The Lancet. Oncology

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

01-08-2015

Seminars in oncology

Toxicity patterns with immunomodulating antibodies and their combinations.

01-06-2015

European journal of cancer (Oxford, England : 1990)

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

01-03-2015

International immunology

Therapeutic use of anti-CTLA-4 antibodies.

01-01-2015

Nature communications

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

15-12-2014

Science translational medicine

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

17-09-2014

Cancer immunology, immunotherapy : CII

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

01-05-2014

Nature

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

03-04-2014

The Lancet. Oncology

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

01-04-2014

Current opinion in oncology

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

01-03-2014

OncoTargets and therapy

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

19-12-2013

European journal of clinical pharmacology

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

01-12-2013

Nature medicine

High-throughput identification of antigen-specific TCRs by TCR gene capture.

01-11-2013

Acta oncologica (Stockholm, Sweden)

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

01-11-2013

Practical neurology

Neurological immune-related adverse events of ipilimumab.

01-08-2013

Cancer immunology, immunotherapy : CII

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

01-03-2013

The American journal of pathology

Targeting BRAFV600E in an inducible murine model of melanoma.

01-09-2012

Oncoimmunology

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

01-08-2012

Current oncology reports

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

01-06-2012

European journal of immunology

Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.

01-03-2012

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

10-01-2012

Melanoma research

Expression of the embryological morphogen Nodal in stage III/IV melanoma.

01-12-2011

Urology

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

01-10-2011

Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma.

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands.

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in PtenLoxP/LoxP;BrafCA/+ Mice.

Biomarkers for outcome upon MAPK inhibition in melanoma.

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab.

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells.

Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

The Use of Dried Blood Spots for Pharmacokinetic Monitoring of Vemurafenib Treatment in Melanoma Patients.

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.

Resection of metastasis and local recurrences of renal cell carcinoma after presurgical targeted therapy: probability of complete local control and outcome.

Comparison of pre-treatment MSKCC and IMDC prognostic risk models in patients with synchronous metastatic renal cell carcinoma treated in the era of targeted therapy.

[No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].

BRAF(V600E) Kinase Domain Duplication Identified in Therapy-Refractory Melanoma Patient-Derived Xenografts.

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.

Targeted treatment and immunotherapy in leptomeningeal metastases from melanoma.

Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.

CANCER IMMUNOLOGY. The "cancer immunogram".

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells.

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma.

Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor.

Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts.

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.

Toxicity patterns with immunomodulating antibodies and their combinations.

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.

Therapeutic use of anti-CTLA-4 antibodies.

Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation.

Synchronous BRAF(V600E) and MEK inhibition leads to superior control of murine melanoma by limiting MEK inhibitor induced skin toxicity.

The effect of seasonal variation and secretion of sunitinib in sweat on the development of hand-foot syndrome.

High-throughput identification of antigen-specific TCRs by TCR gene capture.

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O).

Neurological immune-related adverse events of ipilimumab.

Mimicking homeostatic proliferation in vitro generates T cells with high anti-tumor function in non-lymphopenic hosts.

Targeting BRAFV600E in an inducible murine model of melanoma.

Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.

Immunological heterogeneity of the RCC microenvironment: do targeted therapies influence immune response?

Reduced tumor-antigen density leads to PD-1/PD-L1-mediated impairment of partially exhausted CD8⁺ T cells.

Ipilimumab-induced sarcoidosis in a patient with metastatic melanoma undergoing complete remission.

Expression of the embryological morphogen Nodal in stage III/IV melanoma.

A phase II study of presurgical sunitinib in patients with metastatic clear-cell renal carcinoma and the primary tumor in situ.

This site uses cookies

Dermal Delivery of Constructs Encoding Cre Recombinase to Induce Skin Tumors in Pten^LoxP/LoxP;Braf^CA/+ Mice.